ATM Kinase and the DNA Damage Response

ATM Activation Cascade

ATM is a 370 kDa PI3K-like kinase that normally exists as an inactive homodimer. DNA double-strand breaks are sensed by the MRN complex (MRE11–RAD50–NBS1), which directly recruits ATM and stimulates its kinase activity through NBS1's ATM-binding motif at the C-terminus. ATM undergoes Ser1981 autophosphorylation, releasing active monomers that spread along chromatin flanking the break. TIP60 acetyltransferase, activated by H4K16ac at break sites, acetylates ATM Lys3016 — a required modification for full kinase activation.

Within seconds of DSB formation, ATM phosphorylates histone H2AX at Ser139 (γH2AX) across megabase chromatin domains. MDC1 binds γH2AX and recruits more ATM in a positive feedback loop, amplifying the damage signal. This signal propagation ensures that a single DSB generates a microscopically visible γH2AX focus containing thousands of phosphorylated H2AX molecules — enabling a single break to activate a robust cellular response.

Ataxia-Telangiectasia and Cancer Risk

Biallelic germline ATM mutations cause ataxia-telangiectasia (A-T), a rare autosomal recessive disorder characterised by progressive cerebellar ataxia (beginning in infancy), oculomotor telangiectasias, thymic hypoplasia, combined immunodeficiency, extreme sensitivity to ionising radiation, and ~38% lifetime cancer risk (predominantly T-cell lymphomas and leukaemias). A-T patients cannot undergo standard radiotherapy without catastrophic normal tissue toxicity due to their inability to execute radiation-induced DNA damage checkpoints.

Heterozygous ATM carriers — approximately 1–2% of the general population — have moderately elevated breast cancer risk (~20–25% lifetime vs 12% general population) and elevated pancreatic cancer risk. ATM heterozygosity is now included in most comprehensive hereditary cancer gene panels. Somatic ATM mutations occur in ~15% of chronic lymphocytic leukaemias, ~10% of mantle cell lymphomas, and ~10% of pancreatic cancers. ATM-mutant tumours are often sensitive to platinum chemotherapy and PARP inhibitors due to impaired HR.

Cell Cycle Checkpoint Coordination by ATM

ATM simultaneously activates three cell cycle checkpoints through distinct phosphorylation cascades. At G1/S: ATM phosphorylates CHK2 (Thr68), which phosphorylates and targets CDC25A for proteasomal degradation, preventing CDK2 activation and S-phase entry; ATM also phosphorylates p53 (Ser15) and MDM2 (Ser395), stabilising p53 to transcriptionally induce p21 for sustained CDK2/CDK4 inhibition. At the intra-S checkpoint: ATM phosphorylates NBS1 (Ser343) and SMC1 (Ser957/966) to suppress late origin firing and protect stalled replication forks; ATM also activates FANCD2 for replication fork protection through the Fanconi anaemia pathway. At G2/M: ATM activates CHK1/CHK2 to phosphorylate and inactivate CDC25B/C, preventing CDK1-cyclin B dephosphorylation and mitotic entry with unrepaired DSBs.

ATM-null cancer cells bypass these checkpoints and enter mitosis with unrepaired DSBs, leading to chromosome mis-segregation, micronucleus formation, and further genomic instability. Paradoxically, this checkpoint bypass in ATM-deficient tumours accelerates clonal evolution and selects for cells with additional oncogenic alterations rather than causing uniform lethality — which explains why ATM-null tumours are aggressive despite appearing to have reduced damage-sensing capacity.

ATM Inhibitors and Therapeutic Exploitation of ATM Loss

ATM inhibitors (AZD1390, M3814/peposertib, AZD0156) are being developed as radiosensitisers: by blocking ATM-mediated DSB repair after ionising radiation, they prevent faithful repair of radiation-induced breaks in tumour cells. AZD1390 demonstrates blood-brain barrier penetrance and is in clinical trials for glioblastoma in combination with radiotherapy, exploiting the fact that glioblastoma frequently harbours somatic ATM mutations or NHEJ pathway defects that synergise with external ATM inhibition.

ATM-deficient tumours are synthetically sensitive to PARP inhibitors through HR deficiency (forcing reliance on PARP-mediated SSB repair) and to WEE1 inhibitors (checkpoint bypass forces premature mitosis with unrepaired DSBs). Olaparib demonstrated clinical activity in germline ATM-mutant metastatic prostate cancer in the PROfound trial subgroup analysis. Combinations of ATM inhibitors with PARP inhibitors or topoisomerase II inhibitors aim to exploit ATM-proficient tumours by simultaneously generating DSBs and blocking their repair — a strategy analogous to HR/PARP synthetic lethality in BRCA1/2-deficient tumours.

Key Takeaways

• ·ATM is activated within seconds of DSB detection by the MRN complex, spreading γH2AX marks across megabase chromatin domains to generate a microscopically visible damage focus from a single DSB.
• ·ATM simultaneously activates G1/S (CHK2–CDC25A–CDK2), intra-S (NBS1–SMC1), and G2/M (CHK1/2–CDC25B/C–CDK1) checkpoints, coordinating cell cycle arrest with DSB repair across all phases.
• ·Biallelic ATM loss causes ataxia-telangiectasia with extreme radiosensitivity and ~38% lifetime cancer risk; heterozygous carriers (~1–2% of the population) have moderately elevated breast and pancreatic cancer risk.
• ·ATM-mutant tumours (CLL, mantle cell lymphoma, pancreatic cancer) are sensitised to platinum chemotherapy and PARP inhibitors through HR deficiency, analogous to BRCA1/2-mutant tumours.
• ·ATM inhibitors (AZD1390) are being combined with radiotherapy as radiosensitisers and with PARP inhibitors for synthetic lethality — extending ATM as a therapeutic target beyond ATM-deficient cancer.